drugset / Trial / NCT02406521
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This research study is comparing different drug combinations as a possible treatment for metastatic renal cell carcinoma (mRCC) and bone metastases. The names of the study interventions involved in this study are: * Combination of Radium-223 and Sorafenib * Combination of Radium-223 and Pazopanib
Timeline
- Start
- 2015-04
- Primary completion
- 2017-12
- Completion
- 2019-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pazopanib | Small molecule | — | Oral |
| Subject | Radium-223 dichloride | Other / unclassified | — | Intravenous |
| Subject | Sorafenib | Small molecule | — | Oral |